This past Wednesday, April 5th, the Biden-Harris Administration took a step forward in their implementation of Medicare-related aspects of the Inflation Reduction Act in collaboration with the U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicare Services (CMS). With the overarching goal of reducing prescription drug costs, promoting health equity, and improving access to affordable prescription drug coverage, the new rule takes steps forward through a variety of quality improvements for beneficiaries:
- Cracking Down on Misleading Medicare Advantage and Part D Marketing Schemes
- Removing Barriers to Care Created by Complex Prior Authorization and Utilization Management
- Expanding Access to Behavioral Health Care
- Promoting More Equitable Care
- Implementing President Biden’s New Prescription Drug Law
- Medicare Advantage Value-Based Insurance Design Model Extension
For more information about the recent passed rule and how each of the improvements listed above are being implemented, check out CMS.gov.
2024 Medicare Advantage and Part D Final Rule Fact Sheet: https://www.cms.gov/newsroom/fact-sheets/2024-medicare-advantage-and-part-d-final-rule-cms-4201-f